ANTIBODY-DRUG CONJUGATE (ADC)
Future cancer and other infectious disease treatments require a new type of cargo that precisely delivers the medicine to its specific target without causing undesired side-effects on healthy cells and tissue. This concept is fully demonstrated by antibody-drug conjugates, or ADCs, which combines the accurate targeting feature of a monoclonal antibody with highly cytotoxic payloads to achieve the strike of the lesion site as a precision-guided munition.
PLATFORM
Advanced research facilities and experienced technical teams ensure our continuous success in ADC developments. Our pipeline covers every aspect in the creation of an ADC from antibody design/engineering, synthesis of linkers and drug-linker complexes, to large scale ADC manufacturing. Motivated by innovating technologies, we are also constantly adding new technological platforms to our collection and moving science forward.
ONE-STOP ADC DEVELOPMENT SERVICES
Creating an ADC is like travel to a destination on a highway. It is an elegant multi-step process starting with antigen selection to the generation of a suitable antibody and subsequently the attachment of a cytotoxic drug to form the precision-guided munition. Our comprehensive ADC service is your travel companion. We are dedicated to helping you reach your desired destinations, being a half-way point exit or all the way till the end, and provide you with customized antibodies, linkers, drug-linker complexes, analysis, and consultation.
PRODUCTS
An ADC is comprised of an antibody, a molecular linker, and a cytotoxic payload. Creating an ADC is to put those pieces together, just like building a LEGO set. In our inventory, we have a large collection of ADC building blocks such as linkers, payloads, as well as pre-made toxin-linker sets to help the efficient creation of an ADC. We also carry a library of commonly used ADCs for your quick deployment and concept validation, a series of anti-Ab ADCs for fast screening of ADC-suitable antibodies, as well as a growing arsenal of anti-drug antibodies for the evaluation of ADC metabolism and pharmacokinetic characteristics.
